|
Accounts - 2000
Please
click here to download a PDF version. This can be viewed
using Adobe
Acrobat
Financial Highlights |
Chairman's Statement | Profit and Loss Account
| Balance Sheet
| Cash
Flow Statement | Five-Year Financial
Summary | More
Information
Financial Highlights
Year ended December, 2000
|
2000 |
1999 |
|
N'000 |
N'000 |
| Major balance
sheet items: |
|
|
| Total
Assets |
1,692,070 |
1,734,533 |
| Current
liabilities |
629,847 |
673,596 |
| Long term
liabilities |
51,337 |
63,000 |
| Provisions for
liabilities and charges |
27.279 |
27,279 |
| Shareholder's
funds |
983,607 |
970,658 |
|
Major profit
and loss account items:
|
|
|
| Turnover |
1,032,409 |
1,156,861 |
| (Loss)/Profit
before taxation |
29,406 |
17,374 |
| Taxation |
8,548 |
8,593 |
| (Loss)/Profit
after taxation |
20,858 |
8,781 |
| Dividend
(gross) |
7,909 |
- |
|
Information
per 50k ordinary share based on 131,816,00 (1998- 61,250,000) ordinary
shares:
|
| Earnings per share |
15.82k |
6.66k |
| Stock Exchange
quotation as at 31st December |
N
7.99 |
N
5.00 |
| Dividend per
share |
6.00k |
- |
| Dividend cover
(times) |
2.64 |
- |
| Net assets per
share (actual) |
N
7.46 |
N
7.36 |
|
Number of
employees
|
114
|
170
|
Chairman's Statement
From the 37th Annual General Meeting - 24th July,
2001
Distinguished
Shareholders, Ladies and Gentlemen,
I am pleased to
welcome you all to the 37th Annual General Meeting of our
Company, and to present to you the Annual Report and Accounts
for the year ended 31st December, 2000. In order to appreciate
the results, I shall dwell briefly on the business and
political environment under which we operated.
The Business
and Political Environment
During the year 2000, Nigerians took
advantage of freedom associated with democracy and respect for
human rights, to test the boundaries of freedom of expression.
Consequently, the political environment was catagorised by
tense relations between the executive arm of government and
the legislature.
There were also tense relations between the
federal government and state governments, over issues,
significant examples of which include Sharia law, the battle
for resource control and state police systems.
Ethnic militancy increased during the year
reflecting growing feelings of alienation and grass roots
discontent arising largely from the impact of the poor
economy.
The government's efforts to create a liberal
market-oriented economy, driven by the private sector met with
limited success. One major successful exercise recorded by the
government however, was in its programme of privatising some
of its assets. The exercise was remarkable transparent, with
considerable enthusiasm for the programme expressed by several
consortia made up of local and foreign investors.
On the other hand, efforts to increase the
size and activity of the non-oil, especially the agricultural
and manufacturing sectors, have not been as successful. To
achieve this, the government needs to address the myriad
difficulties arresting the development of the enfeebled
private sector, and also needs to tackle the problems of
collapsing infrastructure and lost confidence in the system.
Outside of telecom and oil sectors, and some multinational
firms, the anticipated increase in foreign investment did not
materialise, partly because investors are yet to be convinced
of the country's economic turnaround and also adequate
security.
The trade union movement, strengthened by
their regained independence, under constitutional rule and the
rule of law, staged several major protests and strikes against
government policy. The most prominent of such actions was the
strike forcing the government to back down on its plans to
deregulate the petroleum sector.
2000 Performance
Our performance during the 2000 financial
year reflects the extent to which we were able to perform, in
spite of significant challenges posed by the operating
environment.
Overall, we continued to battle with the
costs of providing alternative infrastructure to run our
operations, most notable of which was the very poor
electricity supply situation. Our budget, as well as the cost
of maintaining our overworked generating sets.
In the Industrial Chemical Division, the low
production levels of our client companies in the textile,
paint and soap industries meant that we could not meet our
sales projections. Fierce competition from local and imported
producers and suppliers, kept margins at an all time low.
Despite rising costs, including the Naira devaluation, we were
unable to effect price increases. Indeed, we had to sell some
products at losses, to liquidate stocks.
Overall, slim margins compounded by the
lengthy working capital cycle for funding inventory as well as
receivables, led to a loss on the operations year. In the
prevailing environment, our future activities in the chemical business
have come up for review, as it has had a significant and
adverse impact on our performance.
On the other hand, the Pharma Division
recorded significant performance improvement. Divisional sales
improved considerably over the previous year. While we
effected no price increase during the year, we were able to
focus resources more productively, to drive sales and profits
by rationalising unprofitable product lines, and rationalising
our distribution system.
Increased operating costs and distribution
expenses were offset by continued gains form internal
operational efficiencies, which reduced our administrative
expenses significantly. By reducing our exposure to the banks,
and taking advantage of the liquidity situation in the banking
industry, we were able to reduce our interest expenses.
Because of all the foregoing, despite a
reduced turnover in 2000 to N1,032m compared to N1,156m in
1999, we are pleased to have achieved a profit before tax of
N29.4m for the year. This figure, though modest, reflects a
69% increase on the 1999 financial year result of N17.4m, and
comes after a provision for depreciation of N88.4m.
The major area that remains a concern for us
is our high depreciation provision arising from our
reinvestment in plant and equipment, which continues to affect
our results. The only way to combat this effectively is
through increased capacity utilisation. We will continue to
seek ways to effect this, while optimising our net working
capital employed.
Lastly, at the end of the year, our
association with the successor in title to the Hoechst Group,
Aventis formally ended. Sufficient notice of this was received
during the year, and
adequate preparations made to minimise its impact on our
operations. We retain close marketing and technical ties to the largest pharmaceutical group in
the world, Pfizer, the licensor, following its merger with
Warner Lambert, of our strong selling brands, Benylin and
Sloans Liniment amongst others. Strategically, we have
commenced investment in building our own brands, to reduce
business risk arising from losing rights to brands we do not
own.
Outlook for
2001 and Beyond
The
Federal Government budget for the Year 2001 contained several
initiatives to alleviate poverty and to reflate the economy.
It also included adjustments to import tariffs, intended to
assist local manufacturers improve their fortunes. Unfortunately,
in reality, the Year 2001 is turning out to be the most
challenging in recent times, for the manufacturing sector.
The
difference in duty rates between some of our chemical raw
materials and their finished equivalents are insufficient to
create any comparative advantage, when taken against our
higher operating and financial costs.
Of
more concern has been the heavy government spending. We have
already witnessed its impact in high inflation and a sharply
devalued currency. Recent efforts by the Central Bank of
Nigeria to protect the value of the Naira, has led to sharply
increased interest rates, as a result of withdrawing liquidity
from the system.
The
foregoing, in addition to other high operating costs will put
further pressure on our operating margins during the year.
There is little room to pass on these costs to an impoverished
populace through increased prices. We can only continue to
seek avenues to reduce costs through additional internal costs
rationalisation programmes.
We
will also focus on programmes to increase capacity utilization
at our Pharma plant in Otta. This will be achieved through
investing in increased profitable product ranges and brand
extensions as well as expanding strategic manufacturing
alliances with third party companies.
Management will continue to focus on reducing working capital
employed, through effective supply chain management as well as
funds and expense management initiatives.
Management
will build on recent successes in the Pharma business,
investing in strengthening its distribution systems, customer
relationship management and brand building.
In
order to achieve these objectives, we continue to focus on
significantly improving staff caliber, and linking rewards to
performance.
Management intends to take advantage of opportunities arising,
despite the inclement operating environment, to provide steady
growth within the company. We are aided by modern
Pharmaceutical production facilities, an increasingly
invaluable IT enabled database, and a focused group of high caliber
committed staff.
Dividend and
Bonus Issue
Following
two years of not declaring a dividend, it is proposed that a
modest dividend be declared this year, of 6Kobo per share. The
board has also recommended a bonus of one new share for every
six shares owned by shareholders as at 27 June, 2001.
Because the company continues to require retention of cash, to
substitute borrowed funds, to safeguard long-term growth, we
believe that our policy provides the best balance with
expectations of shareholders at this time. This gesture is in
order to compensate our patient shareholders. We also hope
that we can steadily grow the dividend payout in future years,
from this base.
Changes to the
Board
During
the year, Alhaji Adamu Fika resigned from the board, due to
the pressing demands of his national assignment, and in order
to provide opportunity for others to contribute to growing the
business. I am sure you have no objection to my thanking
Alhaji Fika on your behalf, for his years of invaluable
contributions to building NGC, and to wish him every success
in his future endeavours.
After
the end of the financial year, Mr. E.C. Ndiokwere also retired
from the company following 28 years of dedicated and loyal
service. In recognition of his contribution, he is remaining
as a non-executive director, to enable the company continue to
benefit from his wisdom and experience.
During
the year, we invited two gentlemen to join the board, for
which we will seek your approval by ratification.
Mr.
T. Lindsay, a British national, resident in the UK, was a
former employee of Roussel, part of the Hoechst Group, and
what is now known as Aventis. He has been instrumental in
obtaining new and additional licensing collaborations with
global pharmaceutical companies such as Pfizer/Warner Lambert,
and Solvay. His organisation has provided invaluable technical
and marketing support to NGC since 1995.
Alhaji (Dr) Abba Aji is the Managing Director of NSITF. Early
in 2001, NSITF took an interest in NGC, based on its sound
fundamentals, and decided to increase its equity stake as an
institutional investor. This stake presently is more than 10%.
We are very excited to have such an institutional investor
within NGC. We believe that Alhaji Aji will lend both his as
well as NSITF's rich experience to building the fortunes of
NGC.
Management and
Staff Matters
Because
of declining fortunes within the Industrial Chemical Division,
and the need to rationalise administrative staff to reduce
expenses, staff strength declined during the year. Despite the
foregoing, and the strains of operations during the year,
employee relations remained cordial throughout the year,
continuing an eight-year tradition. The management and staff
of the Company deserve commendation for their efforts in this
difficult year.
I am confident that they fully appreciate the enormity of the
challenges they face, going into the future, and are even
better prepared to address these challenges now and in the
future.
Conclusion
In
conclusion, let me express my gratitude to all the
shareholders for their continued support. The Company remains
fundamentally sound, with a very strong asset base, essential
to safeguard sustained long-term growth and development. I am
confident that long term shareholder value and returns are
assured.
Thank
you for your attention.
Abali Muhammadu –
Emir of Fika Chairman
Profit and Loss Account
Year ended December 31, 2000
|
2000 |
1999 |
|
N'000 |
N'000 |
| TURNOVER |
1,032,409 |
1,156,861 |
| Cost of
sales |
(529,645) |
(600,011) |
|
|
|
| GROSS
PROFIT |
502,764 |
556,850 |
|
|
|
| Distribution
expenses |
(70,747) |
(68,092) |
| Administrative
and establishment costs |
(277,209) |
(307,584) |
| Other income |
14,837 |
16,895 |
|
|
|
| OPERATING
PROFIT |
169,645 |
198,069 |
| Interest and
similar charges |
(140,239) |
(180,695) |
|
|
|
| PROFIT ON
ORDINARY ACTIVITIES BEFORE TAXATION |
29,406 |
17,374 |
| Tax on profit on ordinary activities |
(8,548) |
(8,593) |
|
|
|
| RETAINED
PROFIT FOR THE YEAR |
20,858 |
8,781 |
|
|
APPROPRIATIONS
|
|
|
| PROPOSED
DIVIDEND |
7,909 |
- |
| RESERVE
FOR BONUS ISSUE |
10,985 |
- |
| RETAINED
PROFIT TRANSFERRED TO GENERAL RESERVE |
1,964 |
8,781 |
|
| PER SHARE
DATA (KOBO) |
|
|
| Earnings per
share |
15.82K |
6.66k |
| Dividend per
share |
6.00K |
Nil |
|
---------- |
---------- |
Balance
Sheet
At December 31, 2000
|
2000 |
1999 |
|
N'000 |
N'000 |
| FIXED
ASSETS |
558,954 |
635,358 |
| INVESTMENT |
163,987 |
161,962 |
| RESEARCH AND
DEVELOPMENT |
13,104 |
17,420 |
|
________ |
________ |
| CURRENT
ASSETS |
736,045 |
814,740 |
|
________ |
________ |
| Stocks |
724,244 |
584,580 |
| Debtors |
222,453 |
320,926 |
| Cash and bank
balances |
9,328 |
14,287 |
|
________ |
________ |
|
956,025 |
919,793 |
| CREDITORS: |
|
|
| Amount falling
due within one year: |
(629,847) |
(673,596) |
|
________ |
________ |
| NET CURRENT
ASSETS/(LIABILITIES) |
326,178 |
246,197 |
|
________ |
________ |
| TOTAL ASSETS
LESS CURRENT LIABILITIES |
1,062,223 |
1,060,937 |
| |
|
|
| CREDITORS: |
|
|
| Amounts
falling due after more than one year |
(51,337) |
(63,000) |
|
|
|
| PROVISIONS
FOR LIABILITIES AND CHARGES: |
|
|
| Deferred
Taxation |
(27,279) |
(27,279) |
|
________ |
________ |
| NET
ASSETS |
983,607 |
970,658 |
|
--------- |
--------- |
| CAPITAL AND
RESERVES: |
|
|
| Called-up
Share Capital |
65,908 |
65,908 |
| Share
Premium |
377,339 |
377,339 |
| Revaluation
Reserve |
256,850 |
256,850 |
| Reserve for
Bonus Issue |
10,985 |
- |
| General
Reserve |
272,525 |
270,561 |
|
________ |
________ |
|
983,607 |
970,658 |
|
--------- |
--------- |
Cash Flow
Statement
Year ended December 31, 2000
|
2000 |
1999 |
|
N'000 |
N'000 |
|
Cash
flows from Operating activities:
|
|
|
| Cash receipt
from customers |
1,144,945 |
1,120,531 |
| Payment to
suppliers and employees |
(956,471) |
(902,957) |
|
188,474 |
217,574 |
| Income Tax
Paid |
(5,938) |
(5,460) |
| Net Cash
Flow From Operating Activities |
182,536 |
212,114 |
|
Cash
flows from Investing activities:
|
|
|
| Proceeds from
rights issue |
- |
210,078 |
| Purchase of
fixed assets |
(12,842) |
(64,256) |
| Proceeds
from sale of fixed assets |
1,524 |
5,349 |
| Purchase of
investment |
(2,025) |
(15,383) |
| Research and
Development |
4,316 |
1,325 |
| Net Cash
Flow From Investing Activities |
(9,027) |
137,113 |
|
Cash
flows from Financing activities: |
|
|
| Loan
received |
9,610 |
25,000 |
| Interest
paid |
(140,239) |
(180,695) |
| Net Cash
Flow From Financing Activities |
(130,629) |
(155,695) |
| Net Increase
in Cash |
42,880 |
193,532 |
| Cash and
cash equivalents, beginning of the year |
(459,032) |
(652,564) |
| Cash and
cash equivalents, end of the year |
(416,152) |
(459,032) |
|
| Represented
by |
|
|
| Cash in hand
and at bank |
9,328 |
14,287 |
| Bank
overdraft |
(425,480) |
(473,319) |
|
________ |
________ |
|
(416,152) |
(459,032) |
|
--------- |
--------- |
Five-Year
Financial Summary
Year ended December 31,
|
2000 |
1999 |
1998 |
1997 |
1996 |
|
N'000 |
N'000 |
N'000 |
N'000 |
N'000 |
| TURNOVER
AND PROFIT |
|
|
|
|
|
| Turnover |
1,032,409 |
1,156,861 |
972,311 |
1,086,324 |
928,927 |
|
-------- |
-------- |
-------- |
--------- |
-------- |
| Profit before
taxation |
29,406 |
17,374 |
4,855 |
80,900 |
131,017 |
| Taxation |
(8,548) |
(8,593) |
(10,438) |
(7,886) |
(28,045) |
|
_______ |
_______ |
_______ |
_______ |
_______ |
| (Loss)/Profit
after taxation |
20,858 |
8,781 |
(5,583) |
73,014 |
102,972 |
| Dividend |
7,909 |
- |
- |
(30,625) |
(30,625) |
| Debenture
redemption reserve |
- |
- |
- |
(4,000) |
(12,000) |
|
_______ |
_______ |
_______ |
_______ |
_______ |
| Profit/(Loss)
retained |
1,964 |
8,781 |
(5,583) |
38,389 |
60,347 |
|
-------- |
-------- |
-------- |
-------- |
-------- |
| Earnings per
share |
15.82k |
6.66K |
(9.12k) |
119.21k |
168.12k |
|
-------- |
-------- |
-------- |
-------- |
-------- |
| Dividend per
share |
6.00k |
- |
- |
50.00k |
50.00k |
|
-------- |
-------- |
-------- |
-------- |
-------- |
| ASSETS
EMPLOYED |
|
|
|
|
|
| Fixed
assets |
558,954 |
635,358 |
652,682 |
534,986 |
395,485 |
| Investment |
163,987 |
161,962 |
146,579 |
19,692 |
- |
| Research and
Development |
13,104 |
17,420 |
18,745 |
- |
- |
| Net current
assets |
326,178 |
246,197 |
13,989 |
252,273 |
411,697 |
|
_______ |
_______ |
_______ |
_______ |
_______ |
|
1,062,223 |
1,060,937 |
831,995 |
806,951 |
807,182 |
| Provision for
liabilities and charges |
(78,616) |
(90,279) |
(80,196) |
(49,569) |
(92,189) |
|
_______ |
_______ |
_______ |
_______ |
_______ |
|
983,607 |
970,658 |
751,799 |
757,382 |
714,993 |
|
-------- |
-------- |
-------- |
-------- |
-------- |
| FINANCED
BY |
|
|
|
|
|
| Share
capital |
65,908 |
65,908 |
30,625 |
30,625 |
30,625 |
| Reserves |
917,699 |
904,750 |
721,174 |
726,757 |
684,368 |
|
_______ |
_______ |
_______ |
_______ |
_______ |
| Shareholders'
funds |
983,607 |
970,658 |
751,799 |
757,382 |
714,993 |
|
-------- |
-------- |
-------- |
-------- |
-------- |
More
Information
For more information on our accounts, please contact our
company secretary for a copy of our ANNUAL REPORT - contact details »»
|
 |